RE:RE:RE:RE:Price action"The chances of a viable treatment being discovered even in the hands of a competent Pharmaco are vanishingly small and can take a decade to achieve."
The key is that you don't pay for it. The pipeline isn't priced into the stock. You get the upside of billion dollar markets for free.
The avenanthramide pill has now been successfully developed and has been approved for human clinical trials. The results now are just a matter of time. There is considerable scientific literature supporting avenanthramide. Safety is likely already in the bag leaving only efficacy risk. There are many potential applications. Avenanthramide is the reason Gilles joined the company. CZO is the only global producer at scale of natural avenanthramide.
As for fibrosis, you get the excitement of Dr. Ask and Dr. Kolb for free. Dr. Ask is now a leading scientist at the second largest pharma in the world(Novartis). He has published with Boehringer Ingleheim's scientists on one of the leading drugs on the market(Nintedanib). Boehringer Ingleheim went to McMaster wanting to make it inhalable. CZO's drug is inhalable and has been tested with Boehringer Ingleheim's drug. Dr. Ask found CZO's drug may be so good it works all by itself. Adding an already approved drug with it is like an insurance policy if it isn't enough on its own. YBG targets macrophages by nature and macrophages are a supported target for new therapies in the scientific literature.
For the cost of nothing as neither are priced in the stock you get some diversification. They don't even have to make it all the way through trials for the stock to go up and allow the principle investment to be removed.
The Canadian government has provided significant and ongoing financial support, It made the cut after their scientific review. Ronnie Miller from the world's largest biotech company also joined CZO and became Chairman.